SEC Filing Summary: Prima Biomed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima Biomed Ltd, a foreign private issuer headquartered in Sydney, Australia, on October 4, 2017. The filing serves as a report pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The registrant files annual reports under Form 20-F. The document includes Exhibits 99.1 (Appendix 3B) and 99.2 (Appendix 3Y), though the text of these exhibits is not provided in the source input.
Key Financial Metrics
The provided filing text does not contain specific financial data. There are no disclosed values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The document does not include management commentary, forward-looking guidance, risk factors, contingencies, or descriptions of unusual items. The content is limited to the cover page, exhibit index, and signature block.
Investor Verification Checklist
- Verify the contents of Exhibit 99.1 (Appendix 3B) and Exhibit 99.2 (Appendix 3Y) as the specific details of the report are contained within these attachments.
- Confirm the company name discrepancy: The metadata lists "IMMUTEP Ltd," but the filing explicitly identifies the registrant as "PRIMA BIOMED LTD."
- Review the company's most recent Form 20-F for comprehensive financial statements, as this Form 6-K does not include them.